Rhenman & Partners Asset Management Ab Myovant Sciences Ltd. Transaction History

Rhenman & Partners Asset Management Ab

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$7.78 - $14.69 $472,246 - $891,683	60,700 Added 24.35%	310,000 $3.85 Million
Q1 2022 May 13, 2022	SELL	$11.38 - $16.4 $7,966 - $11,479	-700 Reduced 0.28%	249,300 $3.32 Million
Q2 2021 Aug 13, 2021	BUY	$17.07 - $24.56 $426,750 - $614,000	25,000 Added 11.11%	250,000 $5.69 Million
Q1 2021 May 14, 2021	BUY	$20.46 - $25.18 $511,500 - $629,500	25,000 Added 12.5%	225,000 $4.63 Million
Q4 2020 Jan 19, 2021	SELL	$13.8 - $27.62 $2.48 Million - $4.97 Million	-180,000 Reduced 47.37%	200,000 $5.52 Million
Q3 2020 Oct 13, 2020	BUY	$14.05 - $22.6 $3.23 Million - $5.2 Million	230,000 Added 153.33%	380,000 $5.34 Million
Q2 2020 Jul 16, 2020	BUY	$7.34 - $20.84 $1.1 Million - $3.13 Million	150,000 New	150,000 $3.09 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.